Non-Alcoholic Steatohepatitis (NASH) Treatment Market - Global Industry Research Analysis

Non-Alcoholic Steatohepatitis (NASH) Treatment Market Insights

According to Market Research Store, the global non-alcoholic steatohepatitis (NASH) treatment market size was valued at around USD 5.18 billion in 2023 and is estimated to reach USD 23.76 billion by 2032, to register a CAGR of approximately 18.44% in terms of revenue during the forecast period 2024-2032.

The non-alcoholic steatohepatitis (NASH) treatment report provides a comprehensive analysis of the market, including its size, share, growth trends, revenue details, and other crucial information regarding the target market. It also covers the drivers, restraints, opportunities, and challenges till 2032.

To Get more Insights, Request a Free Sample

Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Overview

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) that involves inflammation and damage to the liver, often leading to cirrhosis and liver failure. NASH is primarily associated with obesity, type 2 diabetes, and metabolic syndrome. The treatment landscape for NASH has been evolving as the condition becomes more prevalent. Currently, there is no FDA-approved specific treatment for NASH, but various approaches are being explored. Lifestyle modifications such as weight loss, exercise, and a healthy diet are the cornerstone of managing NASH. Pharmacological interventions, including insulin sensitizers (e.g., pioglitazone), lipid-lowering agents (e.g., statins), and antioxidants (e.g., vitamin E), are commonly used to alleviate symptoms and reduce liver inflammation. Additionally, several novel therapies targeting fibrosis, inflammation, and metabolic pathways are in clinical trials, with promising results.

Key Highlights

• The non-alcoholic steatohepatitis (NASH) treatment market is anticipated to grow at a CAGR of 18.44% during the forecast period.
• The global non-alcoholic steatohepatitis (NASH) treatment market was estimated to be worth approximately USD 5.18 billion in 2023 and is projected to reach a value of USD 23.76 billion by 2032.
• The growth of the non-alcoholic steatohepatitis (NASH) treatment market is being driven by the increasing prevalence of metabolic diseases and an aging population.
• Based on the drug, the vitamin E & pioglitazone segment is growing at a high rate and is projected to dominate the market.
• On the basis of disease stage, the NASH Stage F0 segment is projected to swipe the largest market share.
• In terms of distribution channel, the hospital pharmacies segment is expected to dominate the market.
• By region, North America is expected to dominate the global market during the forecast period.

Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Dynamics

Key Growth Drivers:

• Rising Prevalence of NASH: The global prevalence of NASH is increasing due to the growing rates of obesity, type 2 diabetes, and metabolic syndrome, which are major risk factors for the disease.
• Increasing Awareness and Diagnosis: Improved awareness of NASH among healthcare professionals and the general population is leading to more proactive screening and diagnosis, driving the demand for effective treatments.
• Growing R&D Investments: Pharmaceutical companies are heavily investing in research and development to develop novel therapies for NASH, leading to a robust pipeline of potential treatments.

Restraints:

• Lack of Approved Therapies: Currently, there are limited approved therapies specifically for NASH, creating a significant unmet medical need.
• Complex Pathophysiology: NASH is a complex disease with multiple contributing factors, making it challenging to develop effective treatments that target the underlying causes.
• Challenges in Clinical Trials: Conducting clinical trials for NASH treatments can be challenging due to the slow progression of the disease and the need for long-term studies to assess efficacy and safety.

Opportunities:

• Development of Novel Therapies: The ongoing research and development efforts are expected to yield novel therapies that target specific pathways involved in NASH pathogenesis, offering potential for more effective treatments.
• Combination Therapies: Combining different types of medications or therapies may offer better outcomes than single treatments alone, creating opportunities for combination products and treatment protocols.
• Focus on Personalized Medicine: Tailoring treatment to individual patient characteristics and disease stage could improve outcomes and reduce side effects, opening opportunities for diagnostic tools and personalized treatment plans.

Challenges:

• Accurate Diagnosis: Diagnosing NASH can be challenging, as it often requires liver biopsies, which are invasive and have limitations. Non-invasive diagnostic methods are needed to improve early detection and monitoring of the disease.
• Long-Term Management: NASH is a chronic condition that requires long-term management, and there is a need for treatments that can effectively prevent disease progression and complications.
• Cost and Accessibility: The cost of new NASH therapies is expected to be high, which could limit accessibility, particularly in developing countries or for patients with limited insurance coverage.

Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Report Scope

Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Segmentation Insights

The global non-alcoholic steatohepatitis (NASH) treatment market is divided by drug, disease stage, distribution channel, and region.

Segmentation Insights by Drug

Based on drug, the global non-alcoholic steatohepatitis (NASH) treatment market is divided into vitamin E & pioglitazone, obeticholic acid (OCA), lanifibranor, semaglutide, resmetirom, aramchol, cenicriviroc, and other drugs.

In the non-alcoholic steatohepatitis (NASH) treatment market, Vitamin E & Pioglitazone emerge as the most dominant segment due to their established use in treating NASH, particularly Vitamin E, which has shown beneficial effects on liver histology. These two drugs are commonly prescribed as first-line treatments because of their relatively lower cost and established efficacy in reducing liver inflammation and improving liver function in NASH patients.

Following this, Obeticholic Acid (OCA) stands out as a significant treatment option. It is a selective farnesoid X receptor (FXR) agonist and is in advanced stages of development. OCA has demonstrated promising results in clinical trials, with the ability to reduce liver fibrosis, making it one of the leading drug candidates for NASH treatment.

Next is Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, which has gained attention for its dual benefit in controlling blood sugar levels and potentially reducing liver fat content. It has demonstrated significant weight loss benefits, which is crucial for NASH patients, as obesity and metabolic issues are major contributors to the disease.

Lanifibranor, a peroxisome proliferator-activated receptor (PPAR) agonist, is another drug under clinical investigation. It is considered promising due to its multifaceted action on reducing liver fibrosis and inflammation, though it is still in the clinical trial phase. The potential for approval in the near future keeps it as a significant contender, but it has not yet reached the same level of market dominance as the previous treatments.

Resmetirom is another treatment that targets liver fat and fibrosis. While promising in its mechanism, it is still undergoing trials to confirm its efficacy and safety in treating NASH. Its market presence is currently limited, but it holds potential if future studies continue to support its benefits in reducing liver damage.

Aramchol, a synthetic fatty acid, is designed to reduce liver fat and improve insulin sensitivity. It has shown some positive results in clinical trials, but its development has been slower compared to others, limiting its market dominance for now.

Cenicriviroc, an inhibitor of the CCR2 and CCR5 receptors, targets inflammation and fibrosis. While it has shown promise in reducing liver inflammation and fibrosis in clinical studies, it has not yet gained as much traction in the NASH treatment landscape as some of the other drugs mentioned.

Segmentation Insights by Disease Stage

On the basis of disease stage, the global non-alcoholic steatohepatitis (NASH) treatment market is bifurcated into NASH stage F0, NASH stage F1, NASH stage F2, NASH stage F3, and NASH stage F4.

Starting with NASH Stage F0, which refers to patients with minimal or no fibrosis, this stage represents the smallest segment in terms of treatment focus. While these patients do not show significant liver damage, early intervention with lifestyle modifications, including weight management and diabetes control, may still be recommended. However, pharmacological treatment options are generally less aggressive at this stage, and many therapies are targeted toward more advanced stages of NASH.

NASH Stage F1, indicating mild fibrosis, still presents a relatively manageable situation where the liver has not yet undergone severe scarring. This segment sees increased interest from treatments like Vitamin E & Pioglitazone, which can help prevent further progression of the disease. The treatment approach at this stage is usually focused on slowing the progression and avoiding complications, which contributes to a significant share of the market. Lifestyle changes are crucial, and some patients may benefit from drugs that address insulin resistance.

NASH Stage F2, representing moderate fibrosis, is a stage where more aggressive interventions may become necessary. At this stage, fibrosis is evident, but the liver function remains largely intact. Treatments targeting fibrosis reduction, such as Obeticholic Acid (OCA) and other promising drug candidates like Semaglutide, are often recommended. As liver damage becomes more apparent, the market for drugs that target both fibrosis and liver inflammation grow, making this stage one of the more dominant segments in terms of pharmacological treatment.

NASH Stage F3 represents advanced fibrosis, where liver damage is more pronounced, but cirrhosis has not yet developed. This stage is crucial in terms of treatment, as the risk of progression to cirrhosis (NASH Stage F4) increases. Therapies such as OCA, Lanifibranor, and other advanced treatments targeting fibrosis and inflammation are heavily used in this stage to halt further liver damage and prevent complications like liver failure. This stage, with its higher risk of progression, is one of the most critical segments in the NASH treatment market, and as such, it commands a significant share.

Finally, NASH Stage F4, or cirrhosis, represents the most severe form of the disease, where irreversible scarring of the liver occurs. This stage is marked by high morbidity and mortality, and the primary goal of treatment is to manage complications such as portal hypertension and liver failure. Although there are few options for reversing cirrhosis, treatments focusing on fibrosis regression, like Obeticholic Acid and Resmetirom, are still crucial in this segment. Liver transplantation may be considered in advanced cases. Due to its severity, this stage commands significant attention, though the available treatment options are limited compared to earlier stages.

Segmentation Insights by Distribution Channel

On the basis of distribution channel, the global non-alcoholic steatohepatitis (NASH) treatment market is bifurcated into hospital pharmacies, retail & specialty pharmacies, and other pharmacies.

Starting with hospital pharmacies, this segment is the most dominant in the NASH treatment market, primarily because many NASH treatments, particularly those in later-stage clinical development or those requiring careful management (such as Obeticholic Acid and Lanifibranor), are often prescribed within hospital settings. Hospital pharmacies are typically equipped to handle more specialized treatments and to monitor patients closely for side effects or efficacy, especially in advanced stages of NASH. This distribution channel also benefits from the growing trend of patients with more severe liver damage being treated in hospital or clinical settings. The hospital pharmacy segment is crucial, especially as many of the more expensive or high-need drugs are administered in a hospital setting, contributing significantly to the market.

Next, retail & specialty pharmacies represent another significant distribution channel. Specialty pharmacies, in particular, have grown in prominence due to the increasing number of biologic and specialty drugs being developed for NASH treatment. These pharmacies cater to patients with chronic diseases, including NASH, who require continuous medication management. Retail pharmacies also serve as a point of access for over-the-counter products, such as Vitamin E, which is commonly used in early-stage NASH treatment. Specialty pharmacies are integral for dispensing drugs that require special handling, such as temperature-controlled storage, and they provide personalized services for chronic disease management. This segment is growing as more treatments become available for outpatient care.

Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Regional Insights

• North America is expected to dominates the global market

In North America, particularly the United States, the NASH treatment market is the largest globally. This dominance is attributed to a high prevalence of risk factors like obesity, type 2 diabetes, and metabolic syndrome, which contribute to the development of NASH. The region benefits from advanced healthcare systems, substantial research and development investments, and a robust pharmaceutical industry, facilitating the rapid adoption of new therapies. Additionally, increased awareness among healthcare professionals and patients has led to early detection and treatment, further propelling market growth.

Europe holds the second-largest share in the NASH treatment market. The region faces a rising burden of NASH, driven by increasing rates of obesity and metabolic disorders. Countries such as Germany, the United Kingdom, and France are actively engaged in research and development to address this health concern. Collaborations between academic institutions and pharmaceutical companies are accelerating the development of effective treatments. Moreover, the prevalence of NASH is significant, with expectations of a sharp rise in cases in the coming years.

The Asia-Pacific region is experiencing rapid growth in the NASH treatment market. Countries like China, India, and Japan are witnessing an increase in NASH cases, largely due to urbanization, dietary changes, and sedentary lifestyles. The region's large patient pool, coupled with rising healthcare expenditures and initiatives to enhance healthcare infrastructure, contributes to the market's expansion. Additionally, the aging population in China is a significant factor, as older adults are more prone to developing conditions such as type 2 diabetes and hypertension, major risk factors for NASH.

In Latin America, the NASH treatment market is emerging, with countries like Brazil and Mexico showing increasing awareness and diagnosis rates. The region is characterized by a growing burden of obesity and metabolic disorders, leading to a higher prevalence of NASH. Investments in healthcare infrastructure and rising healthcare expenditures are creating opportunities for market growth. However, challenges such as limited access to advanced medical treatments and diagnostic tools persist, which may affect the pace of market development.

The Middle East and Africa region has the smallest share in the NASH treatment market. The prevalence of NASH is increasing, driven by rising rates of obesity and metabolic disorders. Countries in the Gulf Cooperation Council (GCC) are particularly affected. Efforts are underway to improve healthcare facilities and access to treatments. However, the market faces challenges such as limited awareness, economic disparities, and resource constraints, which may hinder the rapid adoption of NASH therapies.

Recent Developments:

• In May 2024, the FDA approved Rezdiffra (resmetirom) by Madrigal Pharmaceuticals for adults with noncirrhotic, non-alcoholic steatohepatitis (NASH) and moderate to advanced liver fibrosis. The treatment is intended to be used alongside dietary changes and exercise.
• In August 2024, Shilpa Medicare’s shares rose more than 11% to a record high following the announcement of positive Phase 3 trial results for SMLNUD07 (NorUDCA), a drug for Nonalcoholic Fatty Liver Disease (NAFLD). This breakthrough offers a new treatment option for a condition with limited current therapies.

Non-Alcoholic Steatohepatitis (NASH) Treatment Market: Competitive Landscape

The report provides an in-depth analysis of companies operating in the non-alcoholic steatohepatitis (NASH) treatment market, including their geographic presence, business strategies, product offerings, market share, and recent developments. This analysis helps to understand market competition.

Some of the major players in the global non-alcoholic steatohepatitis (NASH) treatment market include:

• Allergan Plc (Tobira)
• Bristol Myers Squibb
• Galmed Pharmaceuticals
• Genfit SA
• Gilead Sciences Inc.
• Intercept Pharmaceuticals Inc.
• Zydus Cadila
• Inventiva
• AbbVie Inc.
• Galectin Therapeutics Inc.
• Madrigal Pharmaceuticals Inc (Madrigal)
• NGM Biopharmaceuticals, Inc.
• Novo Nordisk A/S

The global non-alcoholic steatohepatitis (NASH) treatment market is segmented as follows:

By Drug

• Vitamin E and Pioglitazone
• Obeticholic Acid (OCA)
• Lanifibranor
• Semaglutide
• Resmetirom
• Aramchol
• Cenicriviroc
• Other Drugs

By Disease Stage

• NASH Stage F0
• NASH Stage F1
• NASH Stage F2
• NASH Stage F3
• NASH Stage F4

By Distribution Channel

• Hospital Pharmacies
• Retail and Specialty Pharmacies
• Other Pharmacies

By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • France
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• The Middle East and Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East Africa

Frequently Asked Questions